Telmisartan, Amlodipine and Flow Mediated Dilation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 576 participants.

Also called NCT01180205

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 576 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01180205
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01180205. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Telmisartan, Amlodipine and Flow Mediated Dilation
Acronym
TEAMSTAprotect
Condition
Hypertension
Intervention (Drug)
Telmisartan
Intervention (Drug)
Amlodipine
Intervention (Drug)
Olmesartan medoxomil
Intervention (Drug)
Hydrochlorothiazide
Lead sponsor
Johannes Gutenberg University Mainz (class: other)

Record details

Record id
cardio:ct-nct01180205
Content hash
dc0901ac32b815e293557c88d1c8f2266cb4f89c00c5ba61df2e64e4054ad947